Literature DB >> 918794

The binding of antituberculous drugs to normal and kwashiorkor serum.

N Buchanan, L A van der Walt.   

Abstract

The protein binding of 6 antituberculous drugs--ethambutol, ethionamide, isoniazid, para-aminosalicylic acid, rifampicin and streptomycin--to normal and kwashiorkor serum has been investigated. The binding of these drugs was mildly decreased in kwashiorkor serum, but not to such an extent as to be of therapeutic importance, except for streptomycin and possibly para-aminosalicylic acid (PAS). With streptomycin there was a 15% increase in the free component in kwashiorkor serum, while with PAS there was a 12% increase in the free component. Of interest is the observation that rifampicin is predominantly bound to the gamma-globulin fraction, both in normal and in kwashiorkor serum. Secondary binding, predominantly to the alpha 1-, alpha 2-and gamma-globulin fractions, was seen quite commonly in kwashiorkor serum in association with diminished albumin binding.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 918794

Source DB:  PubMed          Journal:  S Afr Med J


  6 in total

1.  Protein Binding of First-Line Antituberculosis Drugs.

Authors:  Wael A Alghamdi; Mohammad H Al-Shaer; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.

Authors:  Roger K Verbeeck; Bonifasius S Singu; Dan Kibuule
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

Review 3.  A systematic review of pharmacokinetics studies in children with protein-energy malnutrition.

Authors:  Kazeem A Oshikoya; Helen M Sammons; Imti Choonara
Journal:  Eur J Clin Pharmacol       Date:  2010-06-16       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

Review 5.  Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.

Authors:  Marieke G G Sturkenboom; Anne-Grete Märtson; Elin M Svensson; Derek J Sloan; Kelly E Dooley; Simone H J van den Elsen; Paolo Denti; Charles A Peloquin; Rob E Aarnoutse; Jan-Willem C Alffenaar
Journal:  Clin Pharmacokinet       Date:  2021-03-06       Impact factor: 6.447

6.  Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials.

Authors:  Elin M Svensson; Sofiati Dian; Lindsey Te Brake; Ahmad Rizal Ganiem; Vycke Yunivita; Arjan van Laarhoven; Reinout Van Crevel; Rovina Ruslami; Rob E Aarnoutse
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.